iNotify ApS - CVR: 42686107

2021, EUR

01.05.2023

Bruttoresultat

-637'

Primær drift

-842'

Årets resultat

-773'

Aktiver

658'

Kortfristede aktiver

658'

Egenkapital

-767'

Afkastningsgrad

-128 %

Soliditetsgrad

-117 %

Likviditetsgrad

+500%

Resultat

01.05.2023

Årsrapport	2021 01.05.2023
Nettoomsætning
Bruttoresultat	-636.985
Resultat af primær drift	-842.114
Indtægter af kapitalandele (tilknyttede og associerede)	0
Finansielle indtægter	0
Finansieringsomkostninger	-46.291
Andre finansielle omkostninger	0
Resultat før skat	-888.405
Resultat	-772.770
Forslag til udbytte	0

Aktiver

01.05.2023

Årsrapport	2021 01.05.2023
Kortfristede varebeholdninger	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	305.943
Likvider	352.477
Kortfristede aktiver	658.420
Immaterielle aktiver og goodwill	0
Finansielle anlægsaktiver	0
Materielle aktiver	0
Langfristede aktiver	0
Aktiver	658.420

Aktiver

01.05.2023

Passiver

01.05.2023

Årsrapport	2021 01.05.2023
Forslag til udbytte	0
Egenkapital	-767.391
Hensatte forpligtelser	0
Langfristet gæld til banker	0
Anden langfristet gæld	0
Leverandører af varer og tjenesteydelser	28.058
Kortfristede forpligtelser	37.650
Gældsforpligtelser	1.425.811
Forpligtelser	1.425.811
Passiver	658.420

Passiver

01.05.2023

Nøgletal

01.05.2023

Årsrapport	2021 01.05.2023
Afkastningsgrad	-127,9 %
Dækningsgrad	Na.
Resultatgrad	Na.
Varelagerets omsætningshastighed	Na.
Egenkapitals-forretning	100,7 %
Payout-ratio	Na.
Gældsdæknings-nøgletal	-1.819,2 %
Soliditestgrad	-116,6 %
Likviditetsgrad	1.748,8 %

Resultat

01.05.2023

Gæld

01.05.2023

Årsrapport

01.05.2023

Nyeste:17.09.2021- 31.12.2022(offentliggjort: 01.05.2023)

Beretning

01.05.2023

Dato for ledelsens godkendelse af årsrapporten:2023-04-28

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Board of Directors and the Executive Board have discussed and approved the annual report of iNotify ApS for the financial year as of the establishment of the Company 17 September 2021 - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The company is a small company, founded in September 2021 by Karin Lykke-Hartmann and three co-founders, and now with additional three shareholders. The company's mission and key activities is to develop a treatment for infertility for women who do not benefit from existing treatments. We have identified NTY, a small drug, which in our animal model (mouse) have showed a remarkable effect to promote egg formation and life birth. In 2022, our major goals were: to develop a protocol to test NTY in non-human primates and sign the contract to start to develop the business case and secure funding for the company. We signed a contract with Oregon non-human Primate Center, USA, and had six aged female non-human primates secured for our program. The protocol for placebo and drug administration were agreed and signed by both partners. The monkeys were monitored for ovarian cycling during November and December 2022, and placebo group was initiated in January 2023. We developed a business slide deck and applied for non-diluting funding and obtained an Innobooster grant and a Grant Solutions grant from Innovation Fund Denmark. All activities were conducted timely and as planned, and in agreement with our budget.